Evidence map›Paper›PMID 30124796›Full record

Observational studyEuropean heart journal2018

Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry.

Emmanuelle Vidal-Petiot, Emmanuel Sorbets, Deepak L Bhatt, Gregory Ducrocq, Yedid Elbez, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Kim M Fox and 1 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Emmanuelle Vidal-PetiotPhysiology Department, AP-HP, Hôpital Bichat, INSERM U1149, Centre de Recherche sur l'Inflammation, 46, rue Henri Huchard, Paris, France.
Emmanuel SorbetsNHLI Imperial College, Dovehouse Street, London SW3 6LP ICMS, Royal Brompton Hospital, Sydney Street, London, UK.
Deepak L BhattHarvard Medical School, Brigham and Women's Hospital Heart and Vascular Center, 75 Francis street, Boston, MA, USA.
Gregory DucrocqSorbonne Paris Cité, Paris Diderot University, Paris, France.
Yedid ElbezCardiology Department, AP-HP, Hopital Bichat, FACT (French Alliance for Cardiovascular Trials), an F-CRIN network, INSERM U1148, Laboratory for Vascular Translational Science, 46, rue Henri Huchard, Paris, France.
Roberto FerrariCardiological University Centre of Ferrara, University of Ferrara, Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA), Italy.
Ian FordRobertson Centre for Biostatistics, Boyd Orr Building, University Avenue, University of Glasgow, Glasgow, UK.
Jean-Claude TardifDepartment of Medicine, Montreal Heart Institute, Université de Montreal, 5000 Belanger street, Montreal H1T1C8, PQ, Canada.
Michal TenderaMedical University of Silesia, School of Medicine in Katowice, Departement of Cardiology and Structural Heart Disease, Katowice, Poland.
Kim M FoxNHLI Imperial College, Dovehouse Street, London SW3 6LP ICMS, Royal Brompton Hospital, Sydney Street, London, UK.
Philippe Gabriel StegSorbonne Paris Cité, Paris Diderot University, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRBrigham and Women's Hospital · USFrench Clinical Research Infrastructure Network · FRInserm · FRMaria Cecilia Hospital · ITMedical University of Silesia · PLMontreal Heart Institute · CARoyal Brompton Hospital · GBUniversité Paris Cité · FRUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline on high blood pressure (BP) lowered the threshold defining hypertension and BP target in high-risk patients to 130/80 mmHg. Patients with coronary artery disease and systolic BP 130-139 mmHg or diastolic BP 80-89 mmHg should now receive medication to achieve this target. We aimed to investigate the relationship between BP and cardiovascular events in 'real-life' patients with coronary artery disease considered as having normal BP until the recent guideline. Methods and results: Data from 5956 patients with stable coronary artery disease, no history of hypertension or heart failure, and average BP <140/90 mmHg, enrolled in the CLARIFY registry (November 2009 to June 2010), were analysed. In a multivariable-adjusted Cox proportional hazards model, after a median follow-up of 5.0 years, diastolic BP 80-89 mmHg, but not systolic BP 130-139 mmHg, was associated with increased risk of the primary endpoint, a composite of cardiovascular death, myocardial infarction, or stroke (hazard ratio 2.15, 95% confidence interval 1.22-3.81 vs. 70-79 mmHg and 1.12, 0.64-1.97 vs. 120-129 mmHg). No significant increase in risk for the primary endpoint was observed for systolic BP <120 mmHg or diastolic BP <70 mmHg. Conclusion: In patients with stable coronary artery disease defined as having normal BP according to the 140/90 mmHg threshold, diastolic BP 80-89 mmHg was associated with increased cardiovascular risk, whereas systolic BP 130-139 mmHg was not, supporting the lower diastolic but not the lower systolic BP hypertension-defining threshold and treatment target in coronary artery disease. ClinicalTrials identifier: ISRCTN43070564.

Indexed as

Coronary Artery DiseaseHypertensionPractice Guidelines as TopicAgedBlood PressureFemaleHumansMaleMiddle AgedProspective StudiesRandomized Controlled Trials as Topic

Identifiers

PMID30124796
PMCPMC6234847
OpenAlexW2885907396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.